← Leaderboards
Tamie Chilcote
Activesite Pharmaceuticals, Inc.
$2,409,646
Attributed
$2,409,646
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $699.8K · FY2007–13$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,409,646 · 2
By mechanism
R44$2,184,778 · 1
R43$224,868 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Serine Protease”
- Enrico Di Cera · Washington University$10,631,894
- Kenneth Hugh Pearce · Univ Of North Carolina Chapel Hill$9,381,848
- Michael R. Kanost · Kansas State University$8,552,361
- Toni M. Antalis · Baltimore Va Medical Center$8,413,184
- Judy Lieberman · Boston Children'S Hospital$7,616,099
- Gary Arthur Silverman · Children'S Hospital Boston$7,196,981
Research focus
Serine ProteaseIn VitroLeadSmall MoleculePlasma KallikreinPre-ClinicalRattusAnimal ModelInhibitor/AntagonistOralAnimalsAdultDiabetic RetinopathyMacular EdemaDiabetic RatPharmaceutical PreparationsComplications Of Diabetes MellitusDiabetes MellitusLiquid SubstanceBlindnessEvaluationIn VivoGrantDiabetic
Grant awards (5)
Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy$699,825
R44 · FY2013 · EY · contact PI
Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy$660,118
R44 · FY2012 · EY · contact PI
Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy$389,453
R44 · FY2010 · EY · contact PI
Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy$435,382
R44 · FY2009 · EY · contact PI
Novel Anti-Thrombotic Approach for Treatment of Myocardial Infarction$224,868
R43 · FY2007 · HL · contact PI